| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug-Eluting Stents | 80 | 2022 | 753 | 8.520 |
Why?
|
| Angioplasty, Balloon, Coronary | 88 | 2021 | 1874 | 7.370 |
Why?
|
| Stents | 109 | 2024 | 3280 | 6.840 |
Why?
|
| Coronary Restenosis | 53 | 2021 | 424 | 4.630 |
Why?
|
| Sirolimus | 53 | 2022 | 1565 | 4.060 |
Why?
|
| Coronary Thrombosis | 33 | 2024 | 495 | 3.970 |
Why?
|
| Coronary Artery Disease | 67 | 2023 | 6485 | 3.270 |
Why?
|
| Coronary Stenosis | 28 | 2020 | 833 | 2.980 |
Why?
|
| Myocardial Infarction | 98 | 2022 | 11708 | 2.840 |
Why?
|
| Cardiovascular Agents | 23 | 2022 | 850 | 2.180 |
Why?
|
| Paclitaxel | 28 | 2016 | 1705 | 2.180 |
Why?
|
| Platelet Aggregation Inhibitors | 46 | 2022 | 3070 | 2.100 |
Why?
|
| Endpoint Determination | 22 | 2019 | 601 | 1.970 |
Why?
|
| Creatine Kinase, MB Form | 14 | 2019 | 214 | 1.660 |
Why?
|
| Renal Artery Obstruction | 10 | 2019 | 248 | 1.530 |
Why?
|
| Prosthesis Design | 40 | 2022 | 2103 | 1.420 |
Why?
|
| Coronary Angiography | 64 | 2023 | 4576 | 1.350 |
Why?
|
| Myocardial Revascularization | 11 | 2020 | 841 | 1.350 |
Why?
|
| Coated Materials, Biocompatible | 6 | 2017 | 318 | 1.220 |
Why?
|
| Clinical Trials as Topic | 34 | 2022 | 7908 | 1.200 |
Why?
|
| Acute Coronary Syndrome | 10 | 2023 | 2337 | 1.200 |
Why?
|
| Hemorrhage | 28 | 2022 | 3458 | 1.140 |
Why?
|
| Heart Valve Prosthesis Implantation | 16 | 2023 | 1537 | 1.110 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 17 | 2015 | 641 | 1.110 |
Why?
|
| Polymers | 7 | 2022 | 1621 | 1.060 |
Why?
|
| Aspirin | 21 | 2021 | 3283 | 1.050 |
Why?
|
| Treatment Outcome | 152 | 2023 | 63042 | 1.000 |
Why?
|
| Intermittent Claudication | 7 | 2015 | 309 | 0.970 |
Why?
|
| Thrombosis | 22 | 2022 | 2968 | 0.960 |
Why?
|
| Endarterectomy, Carotid | 10 | 2018 | 546 | 0.940 |
Why?
|
| Immunosuppressive Agents | 22 | 2018 | 4152 | 0.920 |
Why?
|
| Coronary Disease | 29 | 2019 | 6078 | 0.910 |
Why?
|
| Absorbable Implants | 8 | 2022 | 336 | 0.800 |
Why?
|
| Troponin | 5 | 2012 | 524 | 0.790 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2017 | 430 | 0.790 |
Why?
|
| Equipment and Supplies | 3 | 2018 | 281 | 0.740 |
Why?
|
| Metals | 6 | 2019 | 719 | 0.730 |
Why?
|
| Time Factors | 75 | 2020 | 40038 | 0.700 |
Why?
|
| Coronary Vessels | 9 | 2021 | 3106 | 0.700 |
Why?
|
| Terminology as Topic | 9 | 2019 | 1546 | 0.700 |
Why?
|
| Risk Assessment | 50 | 2022 | 23327 | 0.690 |
Why?
|
| Carotid Stenosis | 8 | 2018 | 854 | 0.680 |
Why?
|
| Iliac Artery | 3 | 2015 | 364 | 0.660 |
Why?
|
| Humans | 282 | 2024 | 743811 | 0.620 |
Why?
|
| Device Approval | 2 | 2016 | 163 | 0.580 |
Why?
|
| Pyridines | 11 | 2019 | 2827 | 0.570 |
Why?
|
| Follow-Up Studies | 67 | 2019 | 39001 | 0.570 |
Why?
|
| Cardiology | 4 | 2018 | 1668 | 0.560 |
Why?
|
| Middle Aged | 157 | 2021 | 213241 | 0.560 |
Why?
|
| Angioplasty | 9 | 2015 | 364 | 0.560 |
Why?
|
| Aged | 133 | 2020 | 163178 | 0.560 |
Why?
|
| Blood Vessel Prosthesis Implantation | 12 | 2018 | 1391 | 0.540 |
Why?
|
| Kaplan-Meier Estimate | 28 | 2017 | 6539 | 0.540 |
Why?
|
| Risk Factors | 73 | 2023 | 72252 | 0.530 |
Why?
|
| Graft Occlusion, Vascular | 9 | 2011 | 549 | 0.520 |
Why?
|
| Ticlopidine | 9 | 2017 | 899 | 0.520 |
Why?
|
| Constriction, Pathologic | 6 | 2015 | 1108 | 0.510 |
Why?
|
| Financial Management | 1 | 2016 | 160 | 0.500 |
Why?
|
| Death | 5 | 2022 | 678 | 0.500 |
Why?
|
| Diabetes Complications | 5 | 2012 | 1360 | 0.500 |
Why?
|
| Postoperative Complications | 22 | 2018 | 15281 | 0.490 |
Why?
|
| Embolism | 9 | 2013 | 407 | 0.490 |
Why?
|
| Male | 169 | 2022 | 349776 | 0.490 |
Why?
|
| Prospective Studies | 57 | 2022 | 53250 | 0.480 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2014 | 58 | 0.480 |
Why?
|
| Female | 170 | 2022 | 380020 | 0.470 |
Why?
|
| Registries | 19 | 2020 | 8090 | 0.460 |
Why?
|
| Accreditation | 1 | 2016 | 452 | 0.450 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2023 | 2200 | 0.450 |
Why?
|
| Cerebral Revascularization | 2 | 2012 | 238 | 0.450 |
Why?
|
| Stroke | 17 | 2021 | 9975 | 0.440 |
Why?
|
| Diabetic Angiopathies | 3 | 2013 | 819 | 0.430 |
Why?
|
| Donor Selection | 1 | 2014 | 201 | 0.430 |
Why?
|
| Academies and Institutes | 2 | 2012 | 317 | 0.420 |
Why?
|
| Patient Selection | 13 | 2017 | 4210 | 0.420 |
Why?
|
| Myocardial Ischemia | 8 | 2015 | 2150 | 0.410 |
Why?
|
| Proportional Hazards Models | 23 | 2017 | 12354 | 0.410 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 432 | 0.410 |
Why?
|
| Angina Pectoris, Variant | 1 | 2011 | 55 | 0.410 |
Why?
|
| Aortic Valve | 8 | 2018 | 1920 | 0.410 |
Why?
|
| Drug Therapy, Combination | 19 | 2022 | 6487 | 0.410 |
Why?
|
| Coronary Circulation | 8 | 2015 | 1572 | 0.400 |
Why?
|
| United States Food and Drug Administration | 4 | 2018 | 1582 | 0.390 |
Why?
|
| Diabetes Mellitus | 8 | 2019 | 5752 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 26 | 2020 | 9944 | 0.380 |
Why?
|
| Cardiovascular Diseases | 13 | 2018 | 15142 | 0.370 |
Why?
|
| Single-Blind Method | 18 | 2018 | 1586 | 0.370 |
Why?
|
| Heart-Assist Devices | 2 | 2023 | 1195 | 0.370 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2012 | 289 | 0.370 |
Why?
|
| Hemodynamics | 1 | 2020 | 4197 | 0.370 |
Why?
|
| Creatine Kinase | 6 | 2013 | 694 | 0.360 |
Why?
|
| Biomedical Research | 3 | 2017 | 3308 | 0.360 |
Why?
|
| Drug Delivery Systems | 9 | 2013 | 2217 | 0.360 |
Why?
|
| Aorta | 2 | 2015 | 2062 | 0.360 |
Why?
|
| Peripheral Arterial Disease | 7 | 2017 | 1188 | 0.360 |
Why?
|
| Hypothermia, Induced | 2 | 2011 | 752 | 0.350 |
Why?
|
| Decision Support Techniques | 3 | 2016 | 1956 | 0.340 |
Why?
|
| Peer Review, Research | 1 | 2012 | 329 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3255 | 0.330 |
Why?
|
| Kidney Failure, Chronic | 5 | 2016 | 2534 | 0.330 |
Why?
|
| Coronary Artery Bypass | 11 | 2020 | 2288 | 0.320 |
Why?
|
| Atherosclerosis | 7 | 2023 | 3445 | 0.310 |
Why?
|
| Consensus | 9 | 2022 | 2954 | 0.300 |
Why?
|
| Survival Rate | 16 | 2019 | 12786 | 0.300 |
Why?
|
| Heart Valve Prosthesis | 6 | 2018 | 1489 | 0.300 |
Why?
|
| Troponin T | 4 | 2019 | 754 | 0.300 |
Why?
|
| Flavins | 2 | 2023 | 17 | 0.290 |
Why?
|
| Aortic Valve Stenosis | 8 | 2018 | 1955 | 0.290 |
Why?
|
| Predictive Value of Tests | 18 | 2019 | 15067 | 0.290 |
Why?
|
| Research Design | 13 | 2023 | 5983 | 0.290 |
Why?
|
| Europe | 13 | 2023 | 3336 | 0.280 |
Why?
|
| Angioplasty, Balloon | 7 | 2013 | 653 | 0.280 |
Why?
|
| Incidence | 22 | 2017 | 20948 | 0.280 |
Why?
|
| Tissue and Organ Procurement | 1 | 2014 | 896 | 0.280 |
Why?
|
| United States | 45 | 2023 | 69859 | 0.270 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 538 | 0.270 |
Why?
|
| Heart Arrest | 2 | 2016 | 1470 | 0.270 |
Why?
|
| Glomerular Filtration Rate | 6 | 2023 | 2167 | 0.270 |
Why?
|
| Prostheses and Implants | 1 | 2013 | 1385 | 0.260 |
Why?
|
| Severity of Illness Index | 20 | 2020 | 15526 | 0.260 |
Why?
|
| Nanoparticles | 1 | 2017 | 1898 | 0.260 |
Why?
|
| Atherectomy, Coronary | 6 | 2003 | 148 | 0.260 |
Why?
|
| Heart Failure | 8 | 2023 | 10896 | 0.250 |
Why?
|
| Electrocardiography | 14 | 2018 | 6441 | 0.250 |
Why?
|
| Luciferases | 2 | 2023 | 733 | 0.250 |
Why?
|
| Medication Adherence | 2 | 2019 | 2063 | 0.250 |
Why?
|
| Double-Blind Method | 21 | 2018 | 12020 | 0.240 |
Why?
|
| Heart Atria | 4 | 2023 | 1357 | 0.240 |
Why?
|
| Logistic Models | 16 | 2015 | 13404 | 0.240 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2291 | 0.240 |
Why?
|
| Tubulin Modulators | 3 | 2013 | 110 | 0.230 |
Why?
|
| Accidents, Traffic | 1 | 2008 | 819 | 0.220 |
Why?
|
| Heart Diseases | 1 | 2016 | 2789 | 0.220 |
Why?
|
| Multivariate Analysis | 14 | 2019 | 12243 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 6 | 2016 | 7270 | 0.210 |
Why?
|
| Blood Vessel Prosthesis | 4 | 2018 | 933 | 0.210 |
Why?
|
| Clinical Competence | 3 | 2016 | 4687 | 0.200 |
Why?
|
| New Zealand | 6 | 2015 | 355 | 0.200 |
Why?
|
| Exercise Therapy | 3 | 2015 | 904 | 0.200 |
Why?
|
| Saphenous Vein | 5 | 2008 | 532 | 0.200 |
Why?
|
| Vasodilator Agents | 2 | 2016 | 974 | 0.200 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 1670 | 0.200 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 3503 | 0.190 |
Why?
|
| Myocardial Reperfusion | 3 | 2010 | 351 | 0.190 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2014 | 452 | 0.190 |
Why?
|
| Calgranulin A | 1 | 2021 | 79 | 0.190 |
Why?
|
| Calgranulin B | 1 | 2021 | 84 | 0.190 |
Why?
|
| Tyrosine | 2 | 2012 | 1462 | 0.190 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2017 | 339 | 0.190 |
Why?
|
| Isoenzymes | 2 | 2004 | 1728 | 0.180 |
Why?
|
| Stroke Volume | 7 | 2023 | 5002 | 0.180 |
Why?
|
| Hypertension | 8 | 2023 | 8480 | 0.180 |
Why?
|
| Renal Artery | 3 | 2023 | 399 | 0.180 |
Why?
|
| Exercise Test | 3 | 2013 | 2074 | 0.180 |
Why?
|
| Inpatients | 2 | 2010 | 2515 | 0.180 |
Why?
|
| Asia | 4 | 2023 | 609 | 0.170 |
Why?
|
| Odds Ratio | 9 | 2015 | 9848 | 0.170 |
Why?
|
| Survival Analysis | 13 | 2018 | 10251 | 0.170 |
Why?
|
| Sex Factors | 9 | 2018 | 10394 | 0.170 |
Why?
|
| Postoperative Care | 2 | 2017 | 1485 | 0.170 |
Why?
|
| Thienopyridines | 1 | 2018 | 12 | 0.170 |
Why?
|
| Equipment Design | 13 | 2011 | 3574 | 0.160 |
Why?
|
| Data Collection | 4 | 2018 | 3339 | 0.160 |
Why?
|
| P-Selectin | 1 | 2021 | 601 | 0.160 |
Why?
|
| Cause of Death | 5 | 2019 | 3580 | 0.160 |
Why?
|
| Australia | 6 | 2013 | 1167 | 0.160 |
Why?
|
| Retreatment | 5 | 2013 | 609 | 0.160 |
Why?
|
| Prosthesis Implantation | 2 | 2023 | 640 | 0.160 |
Why?
|
| Coronary Occlusion | 1 | 2021 | 304 | 0.150 |
Why?
|
| Endovascular Procedures | 4 | 2019 | 1980 | 0.150 |
Why?
|
| Prosthesis Failure | 7 | 2014 | 1203 | 0.150 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2018 | 194 | 0.140 |
Why?
|
| Alloys | 2 | 2014 | 122 | 0.140 |
Why?
|
| Vascular Diseases | 3 | 2022 | 1161 | 0.140 |
Why?
|
| Equipment Safety | 4 | 2011 | 263 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 10 | 2016 | 5388 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2016 | 5787 | 0.140 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 2159 | 0.140 |
Why?
|
| Organophosphorus Compounds | 1 | 2017 | 213 | 0.130 |
Why?
|
| Bayes Theorem | 4 | 2017 | 2307 | 0.130 |
Why?
|
| Albuminuria | 2 | 2016 | 681 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2016 | 623 | 0.130 |
Why?
|
| Chi-Square Distribution | 4 | 2013 | 3503 | 0.130 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2015 | 1421 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2016 | 1516 | 0.130 |
Why?
|
| Confidence Intervals | 5 | 2016 | 2971 | 0.130 |
Why?
|
| Myocardium | 2 | 2012 | 4775 | 0.130 |
Why?
|
| Thrombectomy | 3 | 2008 | 680 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 6 | 2013 | 1676 | 0.130 |
Why?
|
| Retrospective Studies | 15 | 2020 | 77410 | 0.130 |
Why?
|
| Brain Ischemia | 2 | 2021 | 3264 | 0.130 |
Why?
|
| Treatment Failure | 5 | 2013 | 2617 | 0.120 |
Why?
|
| Internationality | 2 | 2017 | 1002 | 0.120 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 177 | 0.120 |
Why?
|
| Recurrence | 11 | 2019 | 8337 | 0.120 |
Why?
|
| Popliteal Artery | 2 | 2014 | 317 | 0.120 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 4931 | 0.120 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 5033 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2003 | 2251 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2019 | 763 | 0.120 |
Why?
|
| Medical Audit | 1 | 2015 | 466 | 0.120 |
Why?
|
| Aged, 80 and over | 19 | 2019 | 57744 | 0.120 |
Why?
|
| Quality of Life | 14 | 2023 | 12788 | 0.120 |
Why?
|
| Sensitivity and Specificity | 7 | 2013 | 14714 | 0.120 |
Why?
|
| Nitrates | 1 | 2015 | 265 | 0.120 |
Why?
|
| Bioprosthesis | 1 | 2018 | 597 | 0.120 |
Why?
|
| Shock | 1 | 2016 | 318 | 0.110 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2014 | 205 | 0.110 |
Why?
|
| Carotid Arteries | 2 | 2015 | 949 | 0.110 |
Why?
|
| Femoral Artery | 3 | 2014 | 845 | 0.110 |
Why?
|
| Smoking | 6 | 2017 | 8984 | 0.110 |
Why?
|
| Chromium Alloys | 2 | 2016 | 77 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2016 | 552 | 0.110 |
Why?
|
| Massachusetts | 7 | 2016 | 8660 | 0.110 |
Why?
|
| Thiophenes | 2 | 2014 | 589 | 0.110 |
Why?
|
| Combined Modality Therapy | 7 | 2019 | 8637 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 642 | 0.110 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 19894 | 0.100 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2012 | 169 | 0.100 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2015 | 314 | 0.100 |
Why?
|
| Comorbidity | 9 | 2018 | 10380 | 0.100 |
Why?
|
| Reference Standards | 2 | 2012 | 1023 | 0.100 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2013 | 230 | 0.100 |
Why?
|
| Safety | 3 | 2019 | 1184 | 0.100 |
Why?
|
| Cardiology Service, Hospital | 1 | 2013 | 246 | 0.100 |
Why?
|
| Prognosis | 9 | 2023 | 29052 | 0.100 |
Why?
|
| Kidney | 4 | 2023 | 7185 | 0.090 |
Why?
|
| Peptides | 2 | 2012 | 4406 | 0.090 |
Why?
|
| Israel | 3 | 2008 | 796 | 0.090 |
Why?
|
| Feasibility Studies | 4 | 2015 | 5078 | 0.090 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 1619 | 0.090 |
Why?
|
| Coronary Care Units | 1 | 2011 | 214 | 0.090 |
Why?
|
| Autopsy | 2 | 2011 | 1020 | 0.090 |
Why?
|
| Reimbursement Mechanisms | 1 | 2016 | 670 | 0.090 |
Why?
|
| Interinstitutional Relations | 1 | 2011 | 240 | 0.090 |
Why?
|
| Filtration | 2 | 2008 | 233 | 0.090 |
Why?
|
| Health Care Costs | 3 | 2014 | 3207 | 0.090 |
Why?
|
| Credentialing | 1 | 2010 | 126 | 0.090 |
Why?
|
| Renin-Angiotensin System | 1 | 2014 | 758 | 0.090 |
Why?
|
| Health Services | 1 | 2014 | 758 | 0.080 |
Why?
|
| Organizational Objectives | 1 | 2011 | 438 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2014 | 2298 | 0.080 |
Why?
|
| Disease-Free Survival | 7 | 2012 | 6895 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 4 | 2016 | 555 | 0.080 |
Why?
|
| Angiography | 1 | 2014 | 1638 | 0.080 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 1525 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2011 | 980 | 0.080 |
Why?
|
| Aortic Diseases | 1 | 2014 | 743 | 0.080 |
Why?
|
| Societies, Medical | 5 | 2018 | 3740 | 0.080 |
Why?
|
| Age Distribution | 1 | 2014 | 2899 | 0.080 |
Why?
|
| Antihypertensive Agents | 2 | 2015 | 2047 | 0.080 |
Why?
|
| Regression Analysis | 5 | 2012 | 6457 | 0.080 |
Why?
|
| Age Factors | 8 | 2016 | 18355 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 6 | 2014 | 1486 | 0.080 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2001 | 337 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2016 | 1826 | 0.080 |
Why?
|
| Disease Management | 3 | 2015 | 2459 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2011 | 674 | 0.080 |
Why?
|
| Cooperative Behavior | 2 | 2014 | 1503 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 1180 | 0.070 |
Why?
|
| Boston | 3 | 2017 | 9310 | 0.070 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 688 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 4033 | 0.070 |
Why?
|
| Atherectomy | 2 | 2015 | 47 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2015 | 1158 | 0.070 |
Why?
|
| Phosphorylcholine | 1 | 2007 | 162 | 0.070 |
Why?
|
| Mitral Valve | 1 | 2015 | 1491 | 0.070 |
Why?
|
| Piperazines | 2 | 2014 | 2487 | 0.070 |
Why?
|
| Education | 1 | 2010 | 543 | 0.070 |
Why?
|
| Catheterization, Peripheral | 1 | 2010 | 345 | 0.070 |
Why?
|
| Acute Disease | 5 | 2008 | 7150 | 0.070 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2007 | 144 | 0.070 |
Why?
|
| District of Columbia | 2 | 2019 | 157 | 0.070 |
Why?
|
| Hospitalization | 7 | 2018 | 10259 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 782 | 0.070 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 875 | 0.070 |
Why?
|
| World Health Organization | 1 | 2012 | 1317 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 996 | 0.070 |
Why?
|
| Radiology, Interventional | 1 | 2010 | 460 | 0.070 |
Why?
|
| Obesity | 2 | 2023 | 12744 | 0.070 |
Why?
|
| Advisory Committees | 2 | 2014 | 775 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2265 | 0.070 |
Why?
|
| Adult | 18 | 2022 | 213889 | 0.060 |
Why?
|
| Walking | 4 | 2015 | 1182 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2012 | 1027 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2020 | 3750 | 0.060 |
Why?
|
| Drug Implants | 1 | 2005 | 241 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 684 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2014 | 2241 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 549 | 0.060 |
Why?
|
| Anticoagulants | 3 | 2019 | 4599 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 426 | 0.060 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 805 | 0.060 |
Why?
|
| Disease Progression | 3 | 2019 | 13273 | 0.060 |
Why?
|
| Prevalence | 4 | 2014 | 15211 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2009 | 717 | 0.060 |
Why?
|
| Echocardiography | 4 | 2018 | 5096 | 0.060 |
Why?
|
| Emergency Treatment | 2 | 2008 | 517 | 0.060 |
Why?
|
| Statistics as Topic | 2 | 2013 | 2369 | 0.060 |
Why?
|
| Endosonography | 1 | 2007 | 610 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2013 | 2455 | 0.060 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2017 | 980 | 0.060 |
Why?
|
| Time | 2 | 2002 | 542 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 622 | 0.060 |
Why?
|
| Cohort Studies | 12 | 2015 | 40545 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 2 | 2010 | 1476 | 0.050 |
Why?
|
| Kidney Diseases | 2 | 2011 | 2146 | 0.050 |
Why?
|
| Ventricular Remodeling | 2 | 2023 | 1225 | 0.050 |
Why?
|
| Dinucleoside Phosphates | 1 | 2022 | 74 | 0.050 |
Why?
|
| Anemia, Pernicious | 1 | 1981 | 19 | 0.050 |
Why?
|
| Hospital Mortality | 4 | 2012 | 5316 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2015 | 482 | 0.050 |
Why?
|
| Vascular Patency | 2 | 2014 | 887 | 0.050 |
Why?
|
| Heart Valve Diseases | 1 | 2009 | 1073 | 0.050 |
Why?
|
| Ventricular Function, Left | 2 | 2023 | 3660 | 0.050 |
Why?
|
| American Heart Association | 2 | 2015 | 1057 | 0.050 |
Why?
|
| Ischemia | 2 | 2022 | 1907 | 0.050 |
Why?
|
| Mass Screening | 1 | 2016 | 5251 | 0.050 |
Why?
|
| Linear Models | 4 | 2016 | 5952 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 2883 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2014 | 1683 | 0.040 |
Why?
|
| Paris | 1 | 2019 | 42 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 2000 | 128 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2021 | 270 | 0.040 |
Why?
|
| Heart | 2 | 2023 | 4460 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 789 | 0.040 |
Why?
|
| Blood Pressure | 4 | 2016 | 8551 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2021 | 526 | 0.040 |
Why?
|
| Pulmonary Circulation | 1 | 2022 | 739 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2014 | 4251 | 0.040 |
Why?
|
| New York | 1 | 2001 | 885 | 0.040 |
Why?
|
| Brachytherapy | 1 | 2007 | 1247 | 0.040 |
Why?
|
| Hypotension, Orthostatic | 1 | 1981 | 255 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 1789 | 0.040 |
Why?
|
| Models, Economic | 2 | 2014 | 712 | 0.040 |
Why?
|
| Medicare | 1 | 2016 | 6565 | 0.040 |
Why?
|
| Lipids | 1 | 2009 | 3307 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 2021 | 409 | 0.040 |
Why?
|
| Recovery of Function | 3 | 2015 | 2922 | 0.040 |
Why?
|
| Contrast Media | 1 | 2011 | 5301 | 0.040 |
Why?
|
| Reoperation | 2 | 2004 | 4200 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2008 | 2509 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 2000 | 427 | 0.040 |
Why?
|
| Exercise | 2 | 2015 | 5611 | 0.040 |
Why?
|
| Hypertension, Portal | 1 | 2019 | 220 | 0.040 |
Why?
|
| Netherlands | 2 | 2012 | 2170 | 0.040 |
Why?
|
| Adenosine | 1 | 2021 | 825 | 0.040 |
Why?
|
| Health Services Accessibility | 2 | 2011 | 5136 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 1996 | 209 | 0.030 |
Why?
|
| Sutures | 1 | 2018 | 299 | 0.030 |
Why?
|
| South Africa | 2 | 2015 | 1731 | 0.030 |
Why?
|
| Angina Pectoris | 2 | 2011 | 977 | 0.030 |
Why?
|
| Canada | 2 | 2015 | 2064 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2281 | 0.030 |
Why?
|
| Radiography | 3 | 2015 | 7010 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2016 | 131 | 0.030 |
Why?
|
| Control Groups | 1 | 2015 | 105 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2019 | 599 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2015 | 99 | 0.030 |
Why?
|
| Egypt | 1 | 2015 | 100 | 0.030 |
Why?
|
| Western Australia | 1 | 2014 | 41 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2007 | 2877 | 0.030 |
Why?
|
| Suture Techniques | 1 | 2000 | 797 | 0.030 |
Why?
|
| South America | 1 | 2015 | 181 | 0.030 |
Why?
|
| ROC Curve | 1 | 2002 | 3527 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2021 | 953 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2018 | 929 | 0.030 |
Why?
|
| Endarterectomy | 1 | 2015 | 195 | 0.030 |
Why?
|
| Causality | 1 | 2001 | 1275 | 0.030 |
Why?
|
| Risk | 3 | 2015 | 9677 | 0.030 |
Why?
|
| Medicine | 2 | 2015 | 945 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 364 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2015 | 970 | 0.030 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 579 | 0.030 |
Why?
|
| Amlodipine | 1 | 2013 | 83 | 0.030 |
Why?
|
| Workflow | 1 | 2018 | 847 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 829 | 0.030 |
Why?
|
| Neointima | 1 | 2013 | 135 | 0.030 |
Why?
|
| Mortality | 2 | 2017 | 2862 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2013 | 163 | 0.030 |
Why?
|
| Catheterization | 1 | 2018 | 1469 | 0.030 |
Why?
|
| Insulin | 1 | 2007 | 6584 | 0.030 |
Why?
|
| Fibrosis | 1 | 2019 | 2030 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 2211 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2000 | 2736 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 2638 | 0.030 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 343 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2003 | 3587 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 1178 | 0.020 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 956 | 0.020 |
Why?
|
| Confidentiality | 1 | 2015 | 613 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2004 | 2758 | 0.020 |
Why?
|
| San Francisco | 1 | 2011 | 159 | 0.020 |
Why?
|
| Young Adult | 2 | 2014 | 56392 | 0.020 |
Why?
|
| Heart Injuries | 1 | 2012 | 210 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2015 | 793 | 0.020 |
Why?
|
| Software Validation | 1 | 2010 | 59 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2019 | 4221 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 923 | 0.020 |
Why?
|
| Warfarin | 1 | 1998 | 1497 | 0.020 |
Why?
|
| Anemia | 1 | 2019 | 1502 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 10940 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1813 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2016 | 1529 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2015 | 7729 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2012 | 355 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 7172 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2011 | 347 | 0.020 |
Why?
|
| Acute Kidney Injury | 2 | 2012 | 1968 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2008 | 6356 | 0.020 |
Why?
|
| Propensity Score | 1 | 2015 | 1781 | 0.020 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2011 | 362 | 0.020 |
Why?
|
| Quality of Health Care | 2 | 2015 | 4370 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 1841 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2012 | 5986 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2013 | 1958 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2014 | 985 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2014 | 1184 | 0.020 |
Why?
|
| Health Status | 2 | 2017 | 4031 | 0.020 |
Why?
|
| Emergency Service, Hospital | 2 | 2011 | 7658 | 0.020 |
Why?
|
| Comprehension | 1 | 2012 | 610 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 1147 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1996 | 2162 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 934 | 0.020 |
Why?
|
| Drug Costs | 1 | 2014 | 1105 | 0.020 |
Why?
|
| Pilot Projects | 3 | 2012 | 8316 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2760 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 1531 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 546 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2018 | 1796 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 9272 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 979 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2009 | 1185 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 1301 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 1918 | 0.020 |
Why?
|
| Activities of Daily Living | 2 | 2008 | 2419 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2017 | 21733 | 0.020 |
Why?
|
| Platelet Count | 1 | 2008 | 780 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2007 | 463 | 0.020 |
Why?
|
| Algorithms | 2 | 2009 | 13869 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2008 | 404 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2012 | 1099 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2016 | 2071 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2014 | 2707 | 0.010 |
Why?
|
| Health Planning Guidelines | 1 | 2004 | 163 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 2007 | 926 | 0.010 |
Why?
|
| Belgium | 1 | 2002 | 103 | 0.010 |
Why?
|
| Quebec | 1 | 2002 | 134 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 2267 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 1240 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2006 | 601 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2008 | 1183 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2014 | 2657 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2001 | 236 | 0.010 |
Why?
|
| Hemorheology | 1 | 2001 | 145 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2012 | 2528 | 0.010 |
Why?
|
| Heart Rate | 1 | 2012 | 4091 | 0.010 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 1917 | 0.010 |
Why?
|
| Neural Conduction | 1 | 1981 | 441 | 0.010 |
Why?
|
| Cineangiography | 1 | 1999 | 124 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2009 | 1859 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2505 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 2291 | 0.010 |
Why?
|
| Punctures | 1 | 2000 | 374 | 0.010 |
Why?
|
| Vitamin B 12 | 1 | 1981 | 527 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 3608 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 1653 | 0.010 |
Why?
|
| Factor XII Deficiency | 1 | 1996 | 4 | 0.010 |
Why?
|
| Patient Admission | 1 | 2004 | 1380 | 0.010 |
Why?
|
| Motor Neurons | 1 | 1981 | 841 | 0.010 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 1996 | 69 | 0.010 |
Why?
|
| Mental Health | 2 | 2000 | 3012 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 3249 | 0.010 |
Why?
|
| Emergencies | 1 | 2001 | 1170 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 1999 | 885 | 0.010 |
Why?
|
| Educational Status | 1 | 2000 | 2540 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20121 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 2715 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 9139 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 2950 | 0.010 |
Why?
|
| Neoplasms | 1 | 2015 | 21675 | 0.000 |
Why?
|
| Adolescent | 1 | 2011 | 85729 | 0.000 |
Why?
|
| Animals | 1 | 2011 | 168660 | 0.000 |
Why?
|